Interferon Gamma Inducible Protein 30: from biological functions to potential therapeutic target in cancers
Sen Zhang,Liwen Ren,Wan Li,Yizhi Zhang,Yihui Yang,Hong Yang,Fang Xu,Wanxin Cao,Xiaoxue Li,Xu Zhang,Guanhua Du,Jinhua Wang
DOI: https://doi.org/10.1007/s13402-024-00979-x
2024-08-14
Abstract:Interferon Gamma Inducible Protein 30 (IFI30), also known as Gamma-Interferon-Inducible Lysosomal Thiol Reductase (GILT), is predominantly found in lysosomes and the cytoplasm. As the sole enzyme identified to catalyze disulfide bond reduction in the endocytic pathway, IFI30 contributes to both major histocompatibility complex (MHC) class I-restricted antigen cross-presentation and MHC class II-restricted antigen processing by decreasing the disulfide bonds of endocytosed proteins. Remarkably, emerging research has revealed that IFI30 is involved in tumorigenesis, tumor development, and the tumor immune response. Targeting IFI30 may provide new strategies for cancer therapy and improve the prognosis of patients. This review provided a comprehensive overview of the research progress on IFI30 in tumor progression, cellular redox status, autophagy, tumor immune response, and drug sensitivity, with a view to providing the theoretical basis for pharmacological intervention of IFI30 in tumor therapy, particularly in immunotherapy.